Nasdaq

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...
Healio

Measurements for HCV cure could be done earlier among people who inject drugs

Please provide your email address to receive an email when new articles are posted on . Measurements taken for HCV cure at 4 weeks produced identical results for people who inject drugs as those taken ...
Nasdaq

Atea Pharmaceuticals Launches Phase 3 C-FORWARD Trial for HCV Treatment Regimen Combining Bemnifosbuvir and Ruzasvir

Atea Pharmaceuticals has announced the initiation of the Phase 3 C-FORWARD trial, which evaluates the combination regimen of bemnifosbuvir and ruzasvir for treating hepatitis C virus (HCV). This trial ...

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected ...

Atea anticipates top line Phase III HCV results midyear 2026 while advancing HEV program

Jean-Pierre Sommadossi, Founder, Chairman, CEO & President, reported substantial clinical progress, highlighting advancement in the global Phase III program evaluating bemnifosbuvir and ruzasvir for ...
Healio

More frequent HCV testing among people who inject drugs may provide ‘very high value’

Please provide your email address to receive an email when new articles are posted on . More frequent HCV testing was cost-effective among people who inject drugs in both high- and low-transmission ...